Avoid common mistakes on your manuscript.
Correction to: Pulm Ther https://doi.org/10.1007/s41030-020-00124-7
The original version of this article unfortunately contained a mistake. In section “Methods”, the word “physiochemical” was incorrectly changed to “physicochemical” in four instances. The correct sentences are as follows:
First sentence of subsection “Ivacaftor PBPK Model”: The physiochemical properties of ivacaftor [e.g., permeability, blood-to-plasma ratio, plasma protein binding, logarithm of acid dissociation constant (pKa)] were obtained from internal sources. All ivacaftor PBPK model parameters are available in Supplementary Table S1.
First sentence of subsection “Lumacaftor PBPK Model”: The physiochemical properties of lumacaftor (e.g., permeability, blood-to-plasma ratio, plasma protein binding, pKa) were obtained from internal sources.
First sentence of subsection “Tezacaftor PBPK Model”: The physiochemical properties of tezacaftor (e.g., permeability, blood-to-plasma ratio, plasma protein binding, pka) were obtained from internal sources.
First sentence of subsection “Elexacaftor PBPK Model”: The physiochemical and ADME properties of elexacaftor (e.g., permeability, blood-to-plasma ratio, plasma protein binding), as well as relevant clinical data, were obtained from internal sources.
The original article has been corrected.
Open Access
This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Tsai, A., Wu, SP., Haseltine, E. et al. Correction to: Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor. Pulm Ther 6, 287 (2020). https://doi.org/10.1007/s41030-020-00128-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s41030-020-00128-3